ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference
September 13 2007 - 6:00AM
PR Newswire (US)
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that Evan M. Levine, ADVENTRX's chief executive
officer, is scheduled to present at the ThinkEquity Partners' Fifth
Annual Growth Conference on Wednesday, September 19th, 2007 at 2:30
p.m. Pacific Daylight Time, 5:30pm Eastern Daylight Time. The
conference takes place in San Francisco at the St. Regis hotel,
September 17 -- 20, 2007. The presentation will be webcast live via
the "Investors" section of the Company's web site at
http://www.adventrx.com/ under "Events." The webcast will be
available for replay for 14 days and can be accessed through the
same link. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals
is a biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can
be found on the Company's web site at http://www.adventrx.com/.
Forward Looking Statements ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks
and assumptions that, if they materialize or do not prove to be
accurate, could cause ADVENTRX's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that ADVENTRX will be unable to
raise sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the ability to timely
enroll subjects in and the results of ADVENTRX's current and
anticipated clinical trials; the potential for ADVENTRX's product
candidates to receive regulatory approval for one or more
indications on a timely basis or at all, and the uncertain process
of seeking regulatory approval; the market potential for ADVENTRX's
product candidates and ADVENTRX's ability to compete in those
markets; and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date when made. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866 Web site: http://www.adventrx.com/ Company News
On-Call: http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024